Bharat CEPI partners with Bharat Biotech, University of Sydney, ExcellGene to develop ‘variant-proof’ COVID-19 vaccine
Bharat Over 60% of youngsters between the 12-14 age group have received the 1st dose of COVID19 vaccine
